Phase Ib trial of superoxide (SO) dismutase (SOD) mimetic GC4419 to reduce chemoradiotherapy (CRT)-induced oral mucositis (OM) in patients (pts) with oral cavity or oropharyngeal carcinoma (OCC).-Reference-Cited by-同舟云学术

Phase Ib trial of superoxide (SO) dismutase (SOD) mimetic GC4419 to reduce chemoradiotherapy (CRT)-induced oral mucositis (OM) in patients (pts) with oral cavity or oropharyngeal carcinoma (OCC).

Published:2016-05-20 Issue:15_suppl Volume:34 Page:10120-10120
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Anderson Carryn M.¹,Allen Bryan G.¹,Sun Wenqing¹,Agarwala Sanjiv S.²,Lee Christopher M.³,Venigalla Madhavi L.⁴,Greenberg Larisa⁵,Adkins Douglas⁶,Chen Yuhchyau⁷,Zhen Weining⁸,Mould Diane R.⁹,Holmlund Jon¹⁰,Brill Jeffrey Mark¹⁰,Sonis Stephen T.¹¹,Buatti John Michael¹

Affiliation:

1. University of Iowa Hospitals and Clinics, Iowa City, IA;

2. St. Luke's Medical Center, Easton, PA;

3. Cancer Care Northwest, Spokane, WA;

4. Lakeland Regional Cancer Center, Lakeland, FL;

5. Allegheny General Hospital, Pittsburgh, PA;

6. Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO;

7. University of Rochester Medical Center, Rochester, NY;

8. University of Nebraska Medical Center, Omaha, NE;

9. Projections Research Inc., Phoenixville, PA;

10. Galera Therapeutics, Inc, Malvern, PA;

11. BioModels, Boston, MA;